Microtentacle Formation in Ovarian Carcinoma
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Immortalized Cell Cultures, Tethering and Imaging
2.2. Primary Cell Lines and Patient-Derived Samples
2.3. Chemosensitivity
2.4. Clustering Assays
2.5. Western Blot Analyses
2.6. Microscopy
2.7. Analyses
3. Results
3.1. Immortalized Ovarian Cancer Cell Lines Display Several McTN Morphologies
3.2. Nearly One-Third of All Ovarian Cancer Cells May Exhibit McTNs
3.3. Freshly Procured Ovarian Cancer Cells from Ascites Also Demonstrate McTNs
3.4. OCCC and OSC Cell Lines Demonstrate Differences in Average McTN Length and Number Per Cell, Suggesting That McTN Morphology Varies by Ovarian Cancer Subtype
3.5. OCCC Overexpress Class III ß-Tubulin (TUBB3) Relative to OSC, and OSC/OCCC Cell Lines Exhibit Microtubule-Stabilizing Post-Translational Modifications of α-Tubulin
3.6. Microtubule Depolymerizing Drugs Decrease the Number and Length of McTNs, Suggesting That Ovarian Cancer McTNs Are Tubulin-Based
3.7. Microtubule-Stabilizing Agents Decrease McTN Dynamics
3.8. Cells That Fail to Form McTNs Demonstrate Differential Expression of α-Tubulin Post-Translational Modifications and Actin-Regulating Proteins Relative to Cells That Form McTNs
3.9. Cluster Formation is More Susceptible to Microtubule Depolymerizing and Stabilizing Agents in Cells that Form McTNs, Suggesting a Role for McTNs in Aggregation
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Torre, L.A.; Bray, F.; Siegel, R.L.; Ferlay, J.; Lortet-Tieulent, J.; Jemal, A. Global cancer statistics, 2012. CA Cancer J. Clin. 2015, 65, 87–108. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ozols, R.F.; Bundy, B.N.; Greer, B.E.; Fowler, J.M.; Clarke-Pearson, D.; Burger, R.A.; Mannel, R.S.; DeGeest, K.; Hartenbach, E.M.; Baergen, R.; et al. Phase III Trial of Carboplatin and Paclitaxel Compared with Cisplatin and Paclitaxel in Patients with Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study. J. Clin. Oncol. 2003, 21, 3194–3200. [Google Scholar] [CrossRef] [PubMed]
- du Bois, A.; Neijt, J.P.; Thigpen, J.T. First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer—A new standard of care? Ann. Oncol. 1999, 10, S35–S41. [Google Scholar] [CrossRef]
- Yang, C.-P.H.; Horwitz, S.B. Taxol®: The First Microtubule Stabilizing Agent. Int. J. Mol. Sci. 2017, 18, 1733. [Google Scholar] [CrossRef] [Green Version]
- Schiff, P.; Horwitz, S.B. Taxol stabilizes microtubules in mouse fibroblast cells. Proc. Natl. Acad. Sci. USA 1980, 77, 1561–1565. [Google Scholar] [CrossRef] [Green Version]
- Ganguly, A.; Yang, H.; Zhang, H.; Cabral, F.; Patel, K.D. Microtubule Dynamics Control Tail Retraction in Migrating Vascular Endothelial Cells. Mol. Cancer Ther. 2013, 12, 2837–2846. [Google Scholar] [CrossRef] [Green Version]
- Komlodi-Pasztor, E.; Sackett, D.; Wilkerson, J.; Fojo, T. Mitosis is not a key target of microtubule agents in patient tumors. Nat. Rev. Clin. Oncol. 2011, 8, 244–250. [Google Scholar] [CrossRef]
- Li, H.; DeRosier, D.J.; Nicholson, W.; Nogales, E.; Downing, K.H. Microtubule Structure at 8 Å Resolution. Structure 2002, 10, 1317–1328. [Google Scholar] [CrossRef] [Green Version]
- Nettles, J.H.; Li, H.; Cornett, B.; Krahn, J.M.; Snyder, J.P.; Downing, K.H. The Binding Mode of Epothilone A on α,ß-Tubulin by Electron Crystallography. Science 2004, 305, 866–869. [Google Scholar] [CrossRef]
- Lee, F.Y.F.; Smykla, R.; Johnston, K.; Menard, K.; McGlinchey, K.; Peterson, R.W.; Wiebesiek, A.; Vite, G.; Fairchild, C.R.; Kramer, R. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone. Cancer Chemother. Pharmacol. 2009, 63, 201–212. [Google Scholar] [CrossRef] [Green Version]
- Roque, D.; Siegel, E.; Buza, N.; Bellone, S.; Silasi, D.-A.; Huang, G.; Andikyan, V.; Clark, M.; Azodi, M.; Schwartz, P.; et al. Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer. Gynecol. Oncol. 2021, 162, S58. [Google Scholar] [CrossRef]
- Roque, D.M.; Ratner, E.S.; Silasi, D.-A.; Azodi, M.; Rutherford, T.J.; Schwartz, P.E.; Nelson, W.K.; Santin, A.D. Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review. Gynecol. Oncol. 2015, 137, 392–400. [Google Scholar] [CrossRef]
- Whipple, R.A.; Cheung, A.M.; Martin, S.S. Detyrosinated microtubule protrusions in suspended mammary epithelial cells promote reattachment. Exp. Cell Res. 2007, 313, 1326–1336. [Google Scholar] [CrossRef] [Green Version]
- Matrone, M.A.; Whipple, R.A.; Balzer, E.M.; Martin, S.S. Microtentacles Tip the Balance of Cytoskeletal Forces in Circulating Tumor Cells. Cancer Res. 2010, 70, 7737–7741. [Google Scholar] [CrossRef] [Green Version]
- Yoon, J.R.; Whipple, R.A.; Balzer, E.M.; Cho, E.H.; Matrone, M.A.; Peckham, M.; Martin, S.S. Local anesthetics inhibit kinesin motility and microtentacle protrusions in human epithelial and breast tumor cells. Breast Cancer Res. Treat. 2011, 129, 691–701. [Google Scholar] [CrossRef] [Green Version]
- Matrone, M.A.; Whipple, R.A.; Thompson, K.; Cho, E.H.; I Vitolo, M.; Balzer, E.M.; Yoon, J.R.; Ioffe, O.B.; Tuttle, K.C.; Tan, M.; et al. Metastatic breast tumors express increased tau, which promotes microtentacle formation and the reattachment of detached breast tumor cells. Oncogene 2010, 29, 3217–3227. [Google Scholar] [CrossRef] [Green Version]
- Balzer, E.M.; Whipple, R.A.; Cho, E.H.; Matrone, M.A.; Martin, S.S. Antimitotic chemotherapeutics promote adhesive responses in detached and circulating tumor cells. Breast Cancer Res. Treat. 2010, 121, 65–78. [Google Scholar] [CrossRef] [Green Version]
- Penet, M.-F.; Krishnamachary, B.; Wildes, F.B.; Mironchik, Y.; Hung, C.-F.; Wu, T.C.; Bhujwalla, Z.M. Ascites Volumes and the Ovarian Cancer Microenvironment. Front. Oncol. 2018, 8, 595. [Google Scholar] [CrossRef]
- Chakrabarti, K.R.; Andorko, J.I.; Whipple, R.A.; Zhang, P.; Sooklal, E.L.; Martin, S.S.; Jewell, C.M. Lipid tethering of breast tumor cells enables real-time imaging of free-floating cell dynamics and drug response. Oncotarget 2016, 7, 10486–10497. [Google Scholar] [CrossRef] [Green Version]
- Domcke, S.; Sinha, R.; Levine, D.A.; Sander, C.; Schultz, N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat. Commun. 2013, 4, 2126. [Google Scholar] [CrossRef]
- Ory, E.C.; Chen, D.; Chakrabarti, K.R.; Zhang, P.; Andorko, J.I.; Jewell, C.M.; Losert, W.; Martin, S.S. Extracting microtentacle dynamics of tumor cells in a non-adherent environment. Oncotarget 2017, 8, 111567–111580. [Google Scholar] [CrossRef] [Green Version]
- Whipple, R.A.; Matrone, M.A.; Cho, E.; Balzer, E.M.; Vitolo, M.; Yoon, J.R.; Ioffe, O.B.; Tuttle, K.C.; Yang, J.; Martin, S.S. Epithelial-to-Mesenchymal Transition Promotes Tubulin Detyrosination and Microtentacles that Enhance Endothelial Engagement. Cancer Res. 2010, 70, 8127–8137. [Google Scholar] [CrossRef] [Green Version]
- Boggs, A.E.; Vitolo, M.; Whipple, R.A.; Charpentier, M.S.; Goloubeva, O.G.; Ioffe, O.B.; Tuttle, K.C.; Slovic, J.; Lu, Y.; Mills, G.B.; et al. α-Tubulin Acetylation Elevated in Metastatic and Basal-like Breast Cancer Cells Promotes Microtentacle Formation, Adhesion, and Invasive Migration. Cancer Res. 2015, 75, 203–215. [Google Scholar] [CrossRef] [Green Version]
- Roque, D.M.; Bellone, S.; Buza, N.; Romani, C.; Cocco, E.; Bignotti, E.; Ravaggi, A.; Rutherford, T.J.; Schwartz, P.E.; Pecorelli, S.; et al. Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone. Am. J. Obstet. Gynecol. 2013, 209, 62.e1–62.e9. [Google Scholar] [CrossRef]
- Roque, D.M.; Buza, N.; Glasgow, M.; Bellone, S.; Bortolomai, I.; Gasparrini, S.; Cocco, E.; Ratner, E.; Silasi, D.-A.; Azodi, M.; et al. Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel. Clin. Exp. Metastasis 2014, 31, 101–110. [Google Scholar] [CrossRef] [Green Version]
- Lin, Z.-Y.; Kuo, C.-H.; Wu, D.-C.; Chuang, W.-L. Anticancer effects of clinically acceptable colchicine concentrations on human gastric cancer cell lines. Kaohsiung J. Med. Sci. 2016, 32, 68–73. [Google Scholar] [CrossRef] [Green Version]
- Molè-Bajer, J.; Bajer, A.S. Action of taxol on mitosis: Modification of microtubule arrangements and function of the mitotic spindle in Haemanthus endosperm. J. Cell Biol. 1983, 96, 527–540. [Google Scholar] [CrossRef]
- Ono, S. Cofilin-induced structural changes in actin filaments stay local. Proc. Natl. Acad. Sci. USA 2020, 117, 3349–3351. [Google Scholar] [CrossRef]
- Mizuno, K. Signaling mechanisms and functional roles of cofilin phosphorylation and dephosphorylation. Cell Signal. 2013, 25, 457–469. [Google Scholar] [CrossRef]
- Chugh, P.; Clark, A.G.; Smith, M.B.; Cassani, D.A.D.; Dierkes, K.; Ragab, A.; Roux, P.P.; Charras, G.; Salbreux, G.; Paluch, E. Actin cortex architecture regulates cell surface tension. Nat. Cell Biol. 2017, 19, 689–697. [Google Scholar] [CrossRef]
- Simiczyjew, A.; Mazur, A.J.; Dratkiewicz, E.; Nowak, D. Involvement of β- and γ-actin isoforms in actin cytoskeleton organization and migration abilities of bleb-forming human colon cancer cells. PLoS ONE 2017, 12, e0173709. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Webster, D.R.; Gundersen, G.G.; Bulinski, J.C.; Borisy, G.G. Differential turnover of tyrosinated and detyrosinated microtubules. Proc. Natl. Acad. Sci. USA 1987, 84, 9040–9044. [Google Scholar] [CrossRef] [Green Version]
- Whipple, R.A.; Vitolo, M.I.; Boggs, A.E.; Charpentier, M.S.; Thompson, K.; Martin, S.S. Parthenolide and costunolide reduce microtentacles and tumor cell attachment by selectively targeting detyrosinated tubulin independent from NF-κB inhibition. Breast Cancer Res. 2013, 15, R83. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Killilea, A.N.; Csencsits, R.; Le, E.B.N.T.; Patel, A.M.; Kenny, S.J.; Xu, K.; Downing, K.H. Cytoskeletal organization in microtentacles. Exp. Cell Res. 2017, 357, 291–298. [Google Scholar] [CrossRef] [PubMed]
- Østevold, K.; Meléndez, A.V.; Lehmann, F.; Schmidt, G.; Aktories, K.; Schwan, C. Septin remodeling is essential for the formation of cell membrane protrusions (microtentacles) in detached tumor cells. Oncotarget 2017, 8, 76686–76698. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pathak, G.P.; Shah, R.; Kennedy, B.E.; Murphy, J.P.; Clements, D.; Konda, P.; Giacomantonio, M.; Xu, Z.; Schlaepfer, I.R.; Gujar, S. RTN4 Knockdown Dysregulates the AKT Pathway, Destabilizes the Cytoskeleton, and Enhances Paclitaxel-Induced Cytotoxicity in Cancers. Mol. Ther. 2018, 26, 2019–2033. [Google Scholar] [CrossRef] [Green Version]
- Wolf, K.J.; Shukla, P.; Springer, K.; Lee, S.; Coombes, J.; Choy, C.J.; Kenny, S.J.; Xu, K.; Kumar, S. A mode of cell adhesion and migration facilitated by CD44-dependent microtentacles. Proc. Natl. Acad. Sci. USA 2020, 117, 11432–11443. [Google Scholar] [CrossRef]
- Eddy, R.J.; Weidmann, M.D.; Sharma, V.P.; Condeelis, J.S. Tumor Cell Invadopodia: Invasive Protrusions that Orchestrate Metastasis. Trends Cell Biol. 2017, 27, 595–607. [Google Scholar] [CrossRef]
- Ogden, A.; Rida, P.C.G.; Aneja, R. Heading off with the herd: How cancer cells might maneuver supernumerary centrosomes for directional migration. Cancer Metastasis Rev. 2012, 32, 269–287. [Google Scholar] [CrossRef] [Green Version]
- Iida, Y.; Okamoto, A.; Hollis, R.L.; Gourley, C.; Herrington, C.S. Clear cell carcinoma of the ovary: A clinical and molecular perspective. Int. J. Gynecol. Cancer 2021, 31, 605–616. [Google Scholar] [CrossRef]
- Köbel, M.; Kalloger, S.E.; Huntsman, D.G.; Santos, J.L.; Swenerton, K.D.; Seidman, J.D.; Gilks, C.B. Differences in Tumor Type in Low-stage Versus High-stage Ovarian Carcinomas. Int. J. Gynecol. Pathol. 2010, 29, 203–211. [Google Scholar] [CrossRef]
- Oliver, K.E.; Brady, W.E.; Birrer, M.; Gershenson, D.M.; Fleming, G.; Copeland, L.J.; Tewari, K.; Argenta, P.A.; Mannel, R.S.; Secord, A.A.; et al. An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience. Gynecol. Oncol. 2017, 147, 243–249. [Google Scholar] [CrossRef]
- Coulup, S.; Georg, G.I. Revisiting microtubule targeting agents: α-Tubulin and the pironetin binding site as unexplored targets for cancer therapeutics. Bioorganic Med. Chem. Lett. 2019, 29, 1865–1873. [Google Scholar] [CrossRef]
- Eltabbakh, G.H.; Piver, M.S. Extraovarian primary peritoneal carcinoma. Oncology 1998, 12, 825–826. [Google Scholar]
- Kannerstein, M.; Churg, J.; McCaughey, W.; Hill, D. Papillary tumors of the peritoneum in women: Mesothelioma or papillary carcinoma. Am. J. Obstet. Gynecol. 1977, 127, 306–314. [Google Scholar] [CrossRef]
- Parmley, T.H.; Woodruff, J. The ovarian mesothelioma. Am. J. Obstet. Gynecol. 1974, 120, 234–241. [Google Scholar] [CrossRef]
- Xu, J.; Zheng, T.; Hong, W.; Ye, H.; Hu, C.; Zheng, Y. Mechanism for the Decision of Ovarian Surface Epithelial Stem Cells to Undergo Neo-Oogenesis or Ovarian Tumorigenesis. Cell Physiol Biochem. 2018, 50, 214–232. [Google Scholar] [CrossRef]
- Auersperg, N.; Wong, A.S.; Choi, K.C.; Kang, S.K.; Leung, P.C. Ovarian surface epithelium: Biology, endocrinology, and pathology. Endocr. Rev. 2001, 22, 255–288. [Google Scholar] [CrossRef] [Green Version]
- Rust, M.J.; Bates, M.; Zhuang, X. Stochastic optical reconstruction microscopy (STORM) provides sub-diffraction-limit image resolution. Nat. Methods. 2006, 3, 793–795. [Google Scholar] [CrossRef] [Green Version]
- Ross, J.L.; Santangelo, C.D.; Makrides, V.; Fygenson, D.K. Tau induces cooperative Taxol binding to microtubules. Proc. Natl. Acad. Sci. USA 2004, 101, 12910–12915. [Google Scholar] [CrossRef] [Green Version]
- Mozzetti, S.; Ferlini, C.; Concolino, P.; Filippetti, F.; Raspaglio, G.; Prislei, S.; Gallo, D.; Martinelli, E.; Ranelletti, F.O.; Ferrandina, G.; et al. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin. Cancer Res. 2005, 11, 298–305. [Google Scholar] [PubMed]
- Terry, S.J.; Dona, F.; Osenberg, P.; Carlton, J.G.; Eggert, U.S. Capping protein regulates actin dynamics during cytokinetic midbody maturation. Proc. Natl. Acad. Sci. USA 2018, 115, 2138–2143. [Google Scholar] [CrossRef] [Green Version]
- Salbreux, G.; Charras, G.; Paluch, E. Actin cortex mechanics and cellular morphogenesis. Trends Cell Biol. 2012, 22, 536–545. [Google Scholar] [CrossRef]
- Kan, T.; Wang, W.; Ip, P.P.; Zhou, S.; Wong, A.S.; Wang, X.; Yang, M. Single-cell EMT-related transcriptional analysis revealed intra-cluster heterogeneity of tumor cell clusters in epithelial ovarian cancer ascites. Oncogene 2020, 39, 4227–4240. [Google Scholar] [CrossRef] [PubMed]
- Henriksen, J.H.; Stage, J.G.; Schlichting, P.; Winkler, K. Intraperitoneal pressure: Ascitic fluid and splanchnic vascular pressures, and their role in prevention and formation of ascites. Scand. J. Clin. Lab. Invest. 1980, 40, 493–501. [Google Scholar] [CrossRef] [PubMed]
- Klymenko, Y.; Water, R.B.; Weiss-Bilka, H.; Lombard, R.; Liu, Y.; Campbell, L.; Kim, O.; Wagner, D.; Ravosa, M.J.; Stack, M.S. Modeling the effect of ascites-induced compression on onvarian cancer multicellular aggregates. Dis. Models Mech. 2018, 11, dmm034199. [Google Scholar] [CrossRef] [Green Version]
- Nath, S.; Pigula, M.; Khan, A.P.; Hanna, W.; Ruhi, M.K.; Dehkordy, F.M.; Pushpavanam, K.; Rege, K.; Moore, K.; Tsujita, Y.; et al. Flow-induced Shear Stress Confers Resistance to Carboplatin in an Adherent Three-Dimensional Model for Ovarian Cancer: A Role for EGFR-Targeted Photoimmunotherapy Informed by Physical Stress. J. Clin. Med. 2020, 9, 924. [Google Scholar] [CrossRef] [Green Version]
- Sorrin, A.J.; Ruhi, M.K.; Ferlic, N.A.; Karimnia, V.; Polacheck, W.J.; Celli, J.P.; Huang, H.; Rizvi, I. Photodynamic Therapy and the Biophysics of the Tumor Microenvironment. Photochem. Photobiol. 2020, 96, 232–259. [Google Scholar] [CrossRef] [Green Version]
- van Driel, W.J.; Koole, S.N.; Sonke, G.S. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. N. Engl. J. Med. 2018, 378, 1363–1364. [Google Scholar] [CrossRef]
OCCC | OSC | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CCARK1 | CCARK2 | OVTOKO | OVISE | JHOC5 | JHOC7 | JHOC9 | ES2 | TOV21G | Kuramochi | OVSAHO | CAOV3 | COV362 | SKOV3 | OVCAR3 | |
Observations (n) | 25 | 22 | 22 | 27 | 24 | 26 | 24 | 24 | 26 | 23 | 26 | 25 | 19 | 26 | 25 |
A (%) | 64 | 82 | 23 | 48 | 25 | 100 | 67 | 13 | 0 | 0 | 23 | 16 | 21 | 4 | 38 |
SS (%) | 28 | 18 | 64 | 26 | 75 | 0 | 25 | 42 | 46 | 52 | 77 | 60 | 32 | 62 | 13 |
SL (%) | 0 | 0 | 14 | 0 | 0 | 0 | 0 | 46 | 54 | 48 | 0 | 28 | 47 | 35 | 13 |
T (%) | 8 | 0 | 0 | 26 | 0 | 0 | 8 | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 38 |
Dominant Morphology | A | A | SS | A | SS | A | A | SL/SS | SL | SS | SS | SS | SL | SS | T/A |
Treatment | CC-ARK-1 | CC-ARK-2 | OVTOKO | JHOC-5 | JHOC-7 | TOV-21-G | ES-2 | Kuramochi | OVSAHO | CaOV3 | COV-362 | SKOV-3 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Paclitaxel | 0.788 | 0.436 | 4.32 | 0.368 | 1.72 | 0.35 | 1.51 | 1.51 | 0.276 | 2.77 | 2.72 | 1.41 |
Ixabepilone | 2.48 | 2.01 | 2.64 | 1 | 0.965 | 0.83 | 2.99 | 3.81 | 5.37 | 0.315 | 0.315 | 0.6 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Reader, J.C.; Fan, C.; Ory, E.C.-H.; Ju, J.; Lee, R.; Vitolo, M.I.; Smith, P.; Wu, S.; Ching, M.M.N.; Asiedu, E.B.; et al. Microtentacle Formation in Ovarian Carcinoma. Cancers 2022, 14, 800. https://doi.org/10.3390/cancers14030800
Reader JC, Fan C, Ory EC-H, Ju J, Lee R, Vitolo MI, Smith P, Wu S, Ching MMN, Asiedu EB, et al. Microtentacle Formation in Ovarian Carcinoma. Cancers. 2022; 14(3):800. https://doi.org/10.3390/cancers14030800
Chicago/Turabian StyleReader, Jocelyn C., Cong Fan, Eleanor Claire-Higgins Ory, Julia Ju, Rachel Lee, Michele I. Vitolo, Paige Smith, Sulan Wu, Mc Millan Nicol Ching, Emmanuel B. Asiedu, and et al. 2022. "Microtentacle Formation in Ovarian Carcinoma" Cancers 14, no. 3: 800. https://doi.org/10.3390/cancers14030800